← Back to Search

Monoclonal Antibodies

RO7502175 + Atezolizumab for Advanced Cancers

Phase 1
Recruiting
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 5 years
Awards & highlights

Study Summary

This trial tests a new drug to see if it's safe and effective in treating multiple cancers.

Who is the study for?
This trial is for adults with certain advanced solid tumors who have a good performance status, measurable disease, and a life expectancy of at least 12 weeks. They must not be pregnant or breastfeeding, have untreated brain metastases, recent cancer treatments, active hepatitis B/C or tuberculosis, HIV infection, autoimmune diseases or live vaccine administration within the last month.Check my eligibility
What is being tested?
The study tests RO7502175 alone and combined with Atezolizumab in patients with various solid tumors. It's conducted in two parts: first to find the right dose (dose escalation) and then to see how well it works at that dose (dose expansion).See study design
What are the potential side effects?
Possible side effects include reactions related to infusion of the drugs, potential immune system-related issues due to Atezolizumab's action on the body's defenses against cancer cells as well as general drug side effects like fatigue and digestive disturbances.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase Ia: Number of Participants with Dose Limiting Toxicities (DLTs)
Phase Ia: Number of Participants with Treatment Emergent Adverse Events
Phase Ib: Number of Participants with DLTs
+1 more
Secondary outcome measures
Phase Ia and Phase Ib: Duration of Response (DOR)
Serum
Phase Ia and Phase Ib: Objective Response Rate (ORR)
+2 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Phase Ib: ExpansionExperimental Treatment2 Interventions
Participants with select solid tumors will receive a recommended dose of RO7502175, determined in Phase Ib Dose Escalation phase, as an IV infusion, in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Group II: Phase Ib: Dose EscalationExperimental Treatment2 Interventions
Participants in successive cohorts will receive escalating doses of RO7502175, as an IV infusion, in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Group III: Phase Ia: ExpansionExperimental Treatment1 Intervention
Participants with select solid tumors will receive a recommended dose of RO7502175, determined in Phase Ia Dose Escalation phase as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Group IV: Phase Ia: Dose EscalationExperimental Treatment1 Intervention
Participants in successive cohorts will receive escalating doses of RO7502175, as an intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
2017
Completed Phase 3
~5860

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Hepatocellular Carcinoma (HCC) include immunotherapy and targeted therapy. Immunotherapy, such as immune checkpoint inhibitors, works by enhancing the body's immune system to recognize and attack cancer cells. Targeted therapy involves drugs that specifically target molecular pathways critical for cancer cell growth and survival, such as tyrosine kinase inhibitors that block signals needed for tumor growth. These treatments are crucial for HCC patients as they offer more precise and potentially less toxic options compared to traditional chemotherapy, improving outcomes and quality of life.
Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies.

Find a Location

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor
1,542 Previous Clinical Trials
567,717 Total Patients Enrolled
11 Trials studying Hepatocellular Carcinoma
537 Patients Enrolled for Hepatocellular Carcinoma

Media Library

Atezolizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05581004 — Phase 1
Hepatocellular Carcinoma Research Study Groups: Phase Ia: Expansion, Phase Ia: Dose Escalation, Phase Ib: Expansion, Phase Ib: Dose Escalation
Hepatocellular Carcinoma Clinical Trial 2023: Atezolizumab Highlights & Side Effects. Trial Name: NCT05581004 — Phase 1
Atezolizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05581004 — Phase 1
Hepatocellular Carcinoma Patient Testimony for trial: Trial Name: NCT05581004 — Phase 1
~156 spots leftby Jul 2025